T1	Participants 82 142	middle-and-late stage tumor patients receiving chemotherapy]
T2	Participants 326 386	middle-and-late stage tumor patients receiving chemotherapy.
T3	Participants 395 439	Recruited 60 patients were randomly assigned
T4	Participants 733 792	middle-and-late stage tumor patients receiving chemotherapy
